SCHEMBL30977360

SCHEMBL30977360

O=S(=O)(Cl)c1cnc2cc(Cl)ccn12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.40
FGFR3 P22607 4/20 0.40
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TNF P01375 1/20 0.36
FLT3 P36888 1/20 0.36
HPGD P15428 1/20 0.36
PARP1 P09874 1/20 0.34
RIPK2 O43353 2/20 0.33
LYN P07948 1/20 0.33
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
PKM P14618 1/20 0.31
PIK3CA P42336 3/20 0.31
MTOR P42345 2/20 0.31
TRPV4 Q9HBA0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30731672 0.82 TNF (0.33) KDRNPC1RAB9ATNFKDM4E
SCHEMBL792707 0.76 ADORA3 (0.44) NPC1RAB9AFLT3HPGDKDM4E
SCHEMBL17697692 0.75 POLB (0.46) PRMT5WDR77NPC1RAB9ATNF
SCHEMBL11925488 0.72 NPC1 (0.43) KDRFGFR3PRMT5WDR77NPC1
SCHEMBL3030423 0.72 KDR (0.41) KDRFGFR3PRMT5WDR77NPC1
SCHEMBL557273 0.72 KDR (0.41) KDRFGFR3PRMT5WDR77NPC1
SCHEMBL30977530 0.71 PIK3CA (0.37) KDRFGFR3NPC1RAB9APIK3CA
SCHEMBL25215804 0.70 ALDH1A1 (0.35) KDRFGFR3NPC1RAB9ATNF
SCHEMBL16370092 0.70 NPC1 (0.52) KDRFGFR3PRMT5WDR77NPC1
SCHEMBL23103326 0.68 KDR (0.40) KDRFGFR3PRMT5WDR77NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619402-A1 GPR17 MODULATORS AND USES THEREOF Myrobalan Therapeutics, Inc. (US) 2025-09-24 EP disclosed
CN-119613397-A N-heteroaromatic ring-3-sulfonamide compounds and use thereof for preparing GPR17 receptor inhibitors 迈巴制药(南京)有限公司 2025-03-14 CN disclosed
WO-2024104462-A1 GPR17 MODULATORS AND USES THEREOF MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) 2024-05-23 WO disclosed